- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01736488
Clinical Study to Evaluate the Antihypertensive Efficacy and Changes of Neurohormonal Markers of Fimasartan and Atenolol With Exaggerated Blood Pressure Response During Exercise in Essential Hypertensive Patients
A Randomized, Double-Blind, Phase IV Clinical Study to Evaluate the Antihypertensive Efficacy and Changes of Neurohormonal Markers of Fimasartan and Atenolol With Exaggerated Blood Pressure Response During Exercise in Essential Hypertensive Patients
Study Overview
Detailed Description
After subjects have signed informed consent voluntarily, when they are taking hypertension medication, they go through screening period for 7 days including wash-out period.
After screening and wash-out period, subjects take the placebo for 14 days (Maximum 21 days), and evaluate their suitability to Inclusion and Exclusion criteria.
Patients, who evaluated the proper subject for this clinical trial, are allocated to experimental group (Fimasartan 60mg) or Control group (Atenolol 50mg) randomly at a ratio 1:1 and their investigational drugs will be administered daily for the study period (8 weeks). Subjects visit their investigators twice during treatment period, when they take their investigational drugs for 4 weeks, and 8 weeks.
The placebo period will be single-blinded and the treatment allocation in this study will be double-blinded.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Anyang, Korea, Republic of
- Hallym University Medical Center
-
Incheon, Korea, Republic of
- Gachon University Gil Hospital
-
Seoul, Korea, Republic of, 120-752
- Severance Hospital
-
Seoul, Korea, Republic of
- Kangnam Severance Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects who agreed to participate in this clinical trial and submitted the written informed consent
- Subjects aged 20 to 75 years
- Essential hypertension patients who are measured more 140mmHg, less than 170mmHg of sitting systolic blood pressure(SiSBP) or more 90mmHg, less than 110mmHg of sitting diastolic blood pressure(SiDBP) at baseline(Day 0)
- men who are measured more 210mmHg, women who are measured more 190mmHg or increasing more than 50mmHg after exercise at baseline(Day 0)
- Subject who considered to understand this clinical trial, be cooperative,and able to be followed-up whole of the clinical trial period
Exclusion Criteria:
- Patients who are measured the difference of mean blood pressure of one arm under sitting diastolic blood pressure(SiDBP) 10mmHg or SiSBP 20mmHg at screening and baseline visit
- more 170mmHg of mean Sitting systolic blood pressure(SiSBP)or more 110mmHg of mean Sitting diastolic blood pressure(SiDBP) before exercise at baseline(Day 0)
- Patients with secondary hypertension
- Patients with orthostatic hypotension who has sign and symptom
- Patients with severe insulin dependent or uncontrolled diabetes mellitus (HbA1c>9, regimen change of oral hypoglycemic agent, using insulin)
- Patients with severe heart disease, ischemic heart disease within 6 months, peripheral vascular disease, Percutaneous transluminal coronary angiography(PTCA), Coronary artery bypass graft(CABG)
- Patients with significant ventricular tachycardia, atrial fibrillation, atrial flutter or other significant arrhythmia
- Patients with hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, hemodynamically significant aortic valve or mitral valve disease
- Patients with severe cerebrovascular disease
- Patients with known severe or malignancy retinopathy
- Patients with wasting disease, autoimmune disease, connective tissue disease at present and/or previous
- Patients with significant investigations; abnormal renal function (Creatinine more 1.5 times than upper limit of normal), abnormal liver function(AST, ALT more 2 times than upper limit of normal), severe fatty liver disease needed medication
- Patients with surgical and medical disease that is able to be affect to absorption, distribution, metabolism and excretion
- Patients who have a story or evidence of alcohol or drug abuse within 2 years
- Childbearing and breast-feeding women
- Female who plan to become pregnancy or have a possibility of pregnancy but don't prevent conception with acknowledged methods
- Patients with Bronchial Asthma
- Patients expected to live less than 1 year with tumor or chronic disease
- Patients with hepatitis B or C
- Patients with history of allergic reaction to any angiotensin II antagonist
- Patients who took medicine within 12 weeks from screening visit or is going on the progress of other clinical trial
- Subject who are judged unsuitable to participate in this clinical trial by investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Fimasartan 60mg
60mg/day of Fimasartan will be oral administered for the study period (8 weeks)
|
Fimasartan 60mg
Other Names:
|
Active Comparator: Atenolol 50mg
50mg/day of Atenolol will be oral administered for the study period (8 weeks)
|
Atenolol 50mg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The difference of sitting Systolic Blood Pressure(SiSBP) between at the peak compared to at resting
Time Frame: After 8 weeks from baseline visit
|
To compare the difference of sitting Systolic Blood Pressure(SiSBP) at the peak compared to at resting between Fimasartan 60mg group and Atenolol 50mg group
|
After 8 weeks from baseline visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The difference of sitting Diastolic Blood Pressure(SiDBP) at the peak compared to at resting
Time Frame: After 8 weeks from baseline visit
|
To compare the difference of sitting Diastolic Blood Pressure(SiDBP), Heart Rate, Neurohormonal markers at the peak compared to at resting between Fimasartan 60mg group and Atenolol 50mg group
|
After 8 weeks from baseline visit
|
The difference of sitting Systolic Blood Pressure(SiSBP) at each exercising stage compared to at resting
Time Frame: After 8 weeks from baseline visit
|
To compare the difference of sitting Systolic Blood Pressure(SiSBP), sitting Diastolic Blood Pressure(SiDBP), Heart Rate at each exercising stage and at recovery compared to at resting between Fimasartan 60mg group and Atenolol 50mg group
|
After 8 weeks from baseline visit
|
The difference of sitting Systolic Blood Pressure(SiSBP) among at resting, each exercising stage and recovery
Time Frame: After 8 weeks from baseline visit
|
To compare the difference of sitting Systolic Blood Pressure(SiSBP), sitting Diastolic Blood Pressure(SiDBP), Heart Rate, neurohormonal markers among at resting, each exercising stage and recovery between Fimasartan 60mg group and Atenolol 50mg group
|
After 8 weeks from baseline visit
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jong Won Ha, PhD, Yonsei University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Hypertension
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Sympatholytics
- Adrenergic beta-1 Receptor Antagonists
- Atenolol
Other Study ID Numbers
- BR-FA-CT-401
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Addpharma Inc.Completed
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
Clinical Trials on Fimasartan
-
Boryung Pharmaceutical Co., LtdCompleted
-
Boryung Pharmaceutical Co., LtdSeoul National University HospitalCompleted
-
Boryung Pharmaceutical Co., LtdSeoul National University Hospital; Kyungpook National University HospitalCompleted
-
Boryung Pharmaceutical Co., LtdYonsei University; Kyungpook National University HospitalCompletedEssential Hypertension | Hepatic ImpairmentKorea, Republic of
-
Boryung Pharmaceutical Co., LtdCompleted
-
Boryung Pharmaceutical Co., LtdCompleted
-
Boryung Pharmaceutical Co., LtdChonbuk National University Hospital; Samsung Medical Center; Asan Medical Center and other collaboratorsCompletedEssential HypertensionKorea, Republic of
-
Boryung Pharmaceutical Co., LtdCovanceCompletedEssential Hypertension
-
Boryung Pharmaceutical Co., LtdCompletedHypertensionKorea, Republic of
-
Seoul National University HospitalSamsung Medical Center; Chonnam National University Hospital; Korea University... and other collaboratorsUnknownCritical Stenosis of Aortic ValveKorea, Republic of